Rare and unusual adverse thrombotic events and thrombocytopenia may be associated with COVID-19 vaccines from AstraZeneca and Johnson & Johnson (J&J), so called vaccine-associated immune thrombotic thrombocytopenia (VITT). VITT resembles autoimmune heparin-induced thrombocytopenia, a well-known prothrombotic disorder caused by platelet-activating antibodies that recognize multimolecular complexes between cationic platelet factor 4 […]
A systematic review and meta-analysis suggests that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may be associated with protective effects for patients with COVID-19. The analysis included 52 studies that evaluated clinical outcomes among 101 949 total patients, of whom 26.0% were receiving ACEIs or ARBs. When adjusted for […]
A multi-parametric cardiovascular magnetic resonance (CMR) assessment revealed myocardial injury in approximately half of hospitalized COVID-19 patients. A total of 148 hospitalized COVID-19 patients (64 ± 12 years, 70% male, 32% requiring ventilatory support) and troponin elevation discharged from six hospitals in the UK underwent convalescent CMR (including adenosine stress perfusion if indicated) […]
A US retrospective cohort study found no association between angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) use and COVID-19 test positivity. The study included 18 472 patients tested for COVID-19 (mean age 49 years, 40% male, and 69% white), 12.4% were taking either ACEIs or ARBs. A positive […]
A retrospective cohort study in the US suggested that myocardial injury was prevalent among patients hospitalized with COVID-19, and was associated with higher risk of mortality. The study included 2736 patients (median age 66.4 years, 59.6% men) with COVID-19 admitted between February 27th and April 12th, 2020 with troponin-I (normal […]